{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Apogee Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"APGE"},"Address":{"label":"Address","value":"221 CRESCENT STREET,BUILDING 17 SUITE 102B, WALTHAM, Massachusetts, United States"},"Phone":{"label":"Phone","value":"650-394-5230"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts."},"CompanyUrl":{"label":"Company Url","value":"https://www.apogeetherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Carl Dambkowski","title":"Chief Medical Officer"},{"name":"Michael Henderson","title":"Chief Executive Officer & Director"},{"name":"Rebecca L. Dabora","title":"Chief Technical Officer"},{"name":"Tim Piringer","title":"Senior Vice President-Information Technology"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}